The reactivation of IFI16-directed immune responses has the potential to convert HER2-positive breast cancer into immunologically active ‘hot tumors’, thereby augmenting patient responsiveness to trastuzumab treatment (Figure 4, left panels and Table 2) (126). The gene discussed is ERBB2; the disease is breast carcinoma.